

Sarissa is nominating three qualified individuals who are dedicated to unlocking shareholder value at Alkermes



Biogen



The Medicines Company

Bioverativ



Alex Denner, Ph.D.



AMARIN

Arbalet Capital

ARROWHAWK
CAPITAL PARTNERS

Ridgefield Capital



Patrice Bonfiglio



INNOVIVA



The Medicines Company



Sarah Schlesinger, M.D.



Alex Denner, Ph.D.



Work Experience

- Currently:
 - Founding partner and Chief Investment Officer of Sarissa Capital Management LP
- Prior, include:
 - Senior Managing Director at Icahn Capital
 - Portfolio Manager at Viking Global Investors
 - Healthcare portfolio manager at Morgan Stanley Investment Management

Board Experience

- Currently:
 - Biogen Inc. (Chair of Corporate Governance Committee)
 - Ironwood Pharmaceuticals (Chair of Gov-Nom Committee)
 - Attralus, Inc.
- Prior, include:
 - The Medicines Company (Chairman)
 - Bioverativ
 - ARIAD Pharmaceuticals (Chairman)
 - Amylin Pharmaceuticals
 - ImClone Systems (Chairman, Chairman of Executive Committee)



Patrice Bonfiglio



Work Experience

- Currently:
 - President at Sarissa Capital
 - Chief Operating Officer, Chief Financial Officer and Chief Compliance Officer of Sarissa Capital
- Prior, include:
 - Head of Operations at Arbalet Capital
 - Operations Manager at Arrowhawk Capital
 - Senior Accountant at Ridgefield Capital
 - Associate and Fund Accountant at Pequot Capital

Board Experience

- Currently:
 - Amarin Corp

Sarah Schlesinger, M.D.



Work Experience

- Currently:
 - Associate Professor at Rockefeller University
 - Senior Attending Physician at Rockefeller University Hospital
- Prior, include:
 - Scientist at Vaccine Research and Design International AIDS Vaccine Initiative
 - Research Physician at Walter Reed Army Institute of Research

Board Experience

- Currently:
 - Innoviva, Inc. (Chair of Nominating/Corporate Governance Committee)
 - Armata Pharmaceuticals
- Prior, include:
 - The Medicines Company
 - ARIAD Pharmaceuticals (Chair of Science and Medicine Committee)